The influence of Race on Pain Outcomes

种族对疼痛结果的影响

基本信息

项目摘要

DESCRIPTION (provided by applicant): Pain is the most common reason people access healthcare in the United States and has been identified as a major public health problem. Despite this attention, investigators have found racial and ethnic disparities in pain management. In systematic literature reviews, it has been found that African Americans are more at risk than Caucasians for experiencing under-treatment of pain (Cintron & Morrison, 2006; Ezenwa, Ameringer, Ward, & Serlin, 2006). There are also racial differences in the prevalence of pain. In a Center for Disease Control study using the 2002 National Health Interview Survey; it was found that 34% of African Americans compared to 22.6% of Caucasians with arthritis had severe pain (Bolen, Sniezek, Theis, Helmick, & et al., 2005). Consistent with the above report, there are racial differences on the impact of pain. For instance, 59.6% of African Americans compared to 30.3% of Caucasians reported pain severe enough to impact behavior (Riley & Gilbert, 2002). The overall goal of my program of research is to better understand racial disparities in pain management. As a first step toward this goal, I will explore the influence of two race-related stressors, perceived discrimination and hopelessness on disparities in pain management. Perceived discrimination is defined as chronic and routine experiences of unfair treatment. Hopelessness is a negative expectation about one's present and future life. This study will test relationships proposed in a conceptual model which suggests that the effect of race on pain outcomes (pain severity, opioid dose, satisfaction with pain treatment, and quality of life) is mediated by perceived discrimination and hopelessness. The specific aims of this study are (1) to examine the relationship between race and pain outcomes and (2) to test whether perceived discrimination and hopelessness mediate the relationship between race and pain outcomes. This study will be a secondary analysis of data from a large cross-sectional survey of patients with chronic noncancer pain. Understanding the role of perceived discrimination and hopelessness on disparities in pain management may be useful in the future design of culturally appropriate pain management educational interventions for African Americans and culturally sensitive educational interventions for healthcare providers. This study will help reduce the public health problems that arise from poorly treated pain (e.g., unnecessary suffering, delayed healing, and lengthened hospitalization).
描述(由申请人提供):疼痛是人们在美国获得医疗保健的最常见原因,已被确定为主要的公共卫生问题。尽管如此,研究人员还是发现了疼痛管理中的种族和民族差异。在系统性文献综述中,已经发现非洲裔美国人比白人更容易经历疼痛治疗不足的风险(Cintron &莫里森,2006; Ezenwa,Ameringer,Ward,& Serlin,2006)。疼痛的患病率也存在种族差异。在疾病控制中心使用2002年全国健康访谈调查进行的一项研究中;发现34%的非裔美国人患有关节炎,而高加索人的这一比例为22.6%(Bolen、Sniezek、Theis、Helmick等人,2005年)。与上述报告一致,疼痛的影响存在种族差异。例如,59.6%的非洲裔美国人和30.3%的白人报告疼痛严重到足以影响行为(Riley &吉尔伯特,2002)。我的研究计划的总体目标是更好地了解疼痛管理中的种族差异。作为实现这一目标的第一步,我将探讨两个种族相关的压力源,感知歧视和绝望的差异疼痛管理的影响。感知到的歧视被定义为长期和例行的不公平待遇经历。绝望是一种对现在和未来生活的消极期望。本研究将测试一个概念模型中提出的关系,该模型表明种族对疼痛结局(疼痛严重程度,阿片类药物剂量,疼痛治疗满意度和生活质量)的影响是由感知歧视和绝望介导的。本研究的具体目的是(1)检查种族和疼痛结果之间的关系和(2)测试是否感知歧视和绝望调解种族和疼痛结果之间的关系。这项研究将是对慢性非癌性疼痛患者的大型横断面调查数据的二次分析。了解感知歧视和绝望对疼痛管理差异的作用可能有助于未来为非裔美国人设计文化上适当的疼痛管理教育干预措施,并为医疗保健提供者设计文化上敏感的教育干预措施。这项研究将有助于减少因治疗不当而引起的公共卫生问题(例如,不必要的痛苦,延迟愈合,延长住院时间)。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Miriam Omelebele Ezenwa其他文献

Miriam Omelebele Ezenwa的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Miriam Omelebele Ezenwa', 18)}}的其他基金

A Stress and Pain Self-management m-Health App for Adult Outpatients with Sickle Cell Disease
适用于镰状细胞病成人门诊患者的压力和疼痛自我管理移动健康应用程序
  • 批准号:
    10286055
  • 财政年份:
    2020
  • 资助金额:
    $ 2.17万
  • 项目类别:
A Stress and Pain Self-management m-Health App for Adult Outpatients with Sickle Cell Disease
适用于镰状细胞病成人门诊患者的压力和疼痛自我管理移动健康应用程序
  • 批准号:
    10255994
  • 财政年份:
    2020
  • 资助金额:
    $ 2.17万
  • 项目类别:
A Stress and Pain Self-management m-Health App for Adult Outpatients with Sickle Cell Disease
适用于镰状细胞病成人门诊患者的压力和疼痛自我管理移动健康应用程序
  • 批准号:
    10416042
  • 财政年份:
    2020
  • 资助金额:
    $ 2.17万
  • 项目类别:
A Stress and Pain Self-management m-Health App for Adult Outpatients with Sickle Cell Disease
适用于镰状细胞病成人门诊患者的压力和疼痛自我管理移动健康应用程序
  • 批准号:
    10653066
  • 财政年份:
    2020
  • 资助金额:
    $ 2.17万
  • 项目类别:
Planning and Evaluation Core
规划与评估核心
  • 批准号:
    10762129
  • 财政年份:
    2018
  • 资助金额:
    $ 2.17万
  • 项目类别:
The influence of Race on Pain Outcomes
种族对疼痛结果的影响
  • 批准号:
    7483486
  • 财政年份:
    2008
  • 资助金额:
    $ 2.17万
  • 项目类别:

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
  • 批准号:
    31070748
  • 批准年份:
    2010
  • 资助金额:
    34.0 万元
  • 项目类别:
    面上项目

相似海外基金

Tissue tropism of PD-1 therapy in ulcerative colitis and rheumatoid arthritis
PD-1治疗溃疡性结肠炎和类风湿性关节炎的组织向性
  • 批准号:
    MR/Y009681/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.17万
  • 项目类别:
    Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
  • 批准号:
    MR/Y022947/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.17万
  • 项目类别:
    Research Grant
Preclinical development of an extracellular vesicle biotherapeutic for juvenile idiopathic arthritis
幼年特发性关节炎细胞外囊泡生物治疗药物的临床前开发
  • 批准号:
    10068495
  • 财政年份:
    2024
  • 资助金额:
    $ 2.17万
  • 项目类别:
    Collaborative R&D
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
  • 批准号:
    24K19237
  • 财政年份:
    2024
  • 资助金额:
    $ 2.17万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Exploring the inflammatory mediators degraded by MMP-2 in MMP-2-deficient mice with knee arthritis through a novel TMT-TAILS quantitative proteomics
通过新型 TMT-TAILS 定量蛋白质组学探索 MMP-2 缺陷型膝关节炎小鼠中 MMP-2 降解的炎症介质
  • 批准号:
    24K19850
  • 财政年份:
    2024
  • 资助金额:
    $ 2.17万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an adaptive platform trial to prevent Rheumatoid Arthritis in partnership with First Nations People.
与原住民合作开发预防类风湿关节炎的适应性平台试验。
  • 批准号:
    491810
  • 财政年份:
    2023
  • 资助金额:
    $ 2.17万
  • 项目类别:
    Operating Grants
The role of diet, as mediated by the gut microbiome, on childhood arthritis disease activity: a feasibility intervention study.
肠道微生物组介导的饮食对儿童关节炎疾病活动的作用:一项可行性干预研究。
  • 批准号:
    489316
  • 财政年份:
    2023
  • 资助金额:
    $ 2.17万
  • 项目类别:
    Operating Grants
DEMORA: DEep spatial characterization of synovial MacrOphages in Rheumatoid Arthritis
DEMORA:类风湿性关节炎滑膜巨噬细胞的深度空间特征
  • 批准号:
    EP/Y027760/1
  • 财政年份:
    2023
  • 资助金额:
    $ 2.17万
  • 项目类别:
    Fellowship
Investigation of hypoxia-inducible factor-1 (HIF-1) as a novel therapeutic target for juvenile idiopathic arthritis.
研究缺氧诱导因子-1 (HIF-1) 作为幼年特发性关节炎的新治疗靶点。
  • 批准号:
    23K14987
  • 财政年份:
    2023
  • 资助金额:
    $ 2.17万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel first-in-class Therapeutics for Rheumatoid Arthritis
类风湿关节炎的一流新疗法
  • 批准号:
    10696749
  • 财政年份:
    2023
  • 资助金额:
    $ 2.17万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了